

Solving the challenges of logistics, infrastructure, and manufacturing capacity for COVID-19 vaccines

Current limitations of COVID-19 vaccines

- ❗ **Cold Chain:** Vaccines need to be stored and shipped frozen, creating massive logistical challenges.
- 🕒 **2 doses:** Current vaccines need multiple doses to provide protection. This creates compliance and manufacturing challenges

Vaxess is solving this with MIMIX: A single-dose, self-applied COVID patch that is stable at room temperature



- ✅ **Shelf-stable:** Even after weeks of 25°C storage, the MIMIX patch drives powerful immune responses thanks to a novel stabilizing material
- 1x **Single Dose Protection:** MIMIX improves immune responses by 50x over IM injection through breakthrough MIT immunology, "Infection Mimicry".
- 👉 **Self-Applied:** Simple device and shelf-stability enable home-based vaccine delivery for the first time.
- 📊 **Scalable:** With BARDA support, Vaxess is moving towards 100M patch per year production


Improving Nationwide COVID Vaccine Access With:



The user-friendly applicator allows for simple administration



Just 5 minutes of patch wear initiates an extended vaccine release that strongly enhances efficacy



Shelf-stability enabled by advanced materials